-
Celgene May Have Lost Positive Sentiment, But Its Growth Thesis Hasn't Gone Anywhere
Friday, October 27, 2017 - 9:21am | 365Read More...William Blair said in a note the double hit on Celgene Corporation (NASDAQ: CELG)'s Inflammation and Immunology franchise may have reversed positive sentiment, but the company's growth thesis and pipeline optionality remains intact. The firm reiterated its Outperform rating on the shares of the...
-
This Analyst Is Disappointed With Performance Of Celgene's Mongersen, Ozanimod
Friday, June 30, 2017 - 2:23pm | 523Read More...BTIG said in a note on Friday it is disappointed with the performance of Celgene Corporation (NASDAQ: CELG)'s mongersen and ozanimod. Mongersen is Celgene's an anti-inflammatory, anti-sense oligonucleotide, which is being studied to treat Crohn's disease, which is a chronic inflammatory bowel...
